Repligen (RGEN) Akcija Cena
Repligen Cena
Ieņēmumi auga par 23,2 % gadā pēdējos 19 gados līdz 738,26 M USD. Peļņa uz akciju samazinājās par 1,8 % gadā pēdējos 18 gados. Repligen neto marža tagad ir 6,6 %, samazinājusies no 19,1 % pirms dažiem gadiem. Analītiķu mērķa cenas mediāna ir 152,50 USD, t. i. zem pašreizējo cenu par 13,8 %. No 27 analītiķiem 23 iesaka pirkt — kopējais konsenss ir Pirkt.
Repligen akcijas cena
Iegūstiet šos datus caur Eulerpool API
100 000 pieprasījumu/mēn. bez maksas · bez kartes
Repligen biznesa modelis un akciju analīze
Bieži uzdotie jautājumi par Repligen akciju
Repligen Corp's business model is centered around being a leading provider of products and services for the bioprocessing industry. The company focuses on developing and supplying innovative solutions that enhance the production of biologic drugs. Repligen offers a range of products including bioreactors, filtration systems, chromatography resins, and pre-packed columns. By offering these high-quality and reliable solutions, Repligen aims to support biopharmaceutical companies in improving their manufacturing processes, increasing productivity, and ensuring the quality of their products. Repligen Corp is dedicated to driving advancements in the bioprocessing industry by delivering exceptional products and services to its customers.
Repligen Corp is primarily active in the biotechnology and life sciences industries.
Some of the main competitors of Repligen Corp in the market include Thermo Fisher Scientific, Merck KGaA, Danaher Corporation, and GE Healthcare.
Repligen Corp is a prominent bioprocessing company with a rich history. Founded in 1981, Repligen initially focused on the development of diagnostic products and later expanded its scope to include bioprocessing technologies. Over the years, the company has made significant contributions to the life sciences industry, offering innovative solutions for biomanufacturing needs. Today, Repligen is recognized for its high-quality products and services, serving customers globally. With a commitment to advancing bioprocessing efficiency and productivity, Repligen continues to drive innovation in the field, supporting the development and manufacturing of biologics.
Repligen Corp has achieved several significant milestones. The company successfully completed the acquisition of Spectrum Laboratories in 2012, expanding its product portfolio and enhancing its market presence. In 2014, Repligen received FDA approval for its flagship bioprocessing product, Protein A, which revolutionized the purification of monoclonal antibodies. The company continued its growth by acquiring the business unit of Novavax Inc. in 2015, strengthening its position in the bioprocessing market. Repligen Corp also reached a partnership agreement with Navigo Proteins GmbH in 2019, allowing the development of new affinity ligands. These achievements demonstrate Repligen Corp's dedication to innovation and market leadership.
Repligen Corp is primarily present in several countries and regions. These include the United States, Europe, and Asia.
Repligen Corp is a leading bioprocessing company committed to enhancing biologic drug manufacturing processes. The company's corporate philosophy revolves around key values such as innovation, quality, and collaboration. Repligen Corp strives to provide cutting-edge solutions to improve productivity, efficiency, and consistency in bioproduction through its advanced technologies and expertise. With a focus on customer satisfaction and a passion for advancing bioprocessing technologies, Repligen Corp aims to empower customers and contribute to making biologic medicines more accessible for patients worldwide.
Analītiķi pašlaik nosaka vidējo Repligen akcijas mērķa cenu 152,00 USD (mediāna: 152,50 USD), kas ir -14,1 % pret pēdējo cenu. Konsenss balstās uz 27 analītiķu vērtējumiem.
27 analītiķi pašlaik vērtē Repligen akciju: 23 iesaka pirkt, 4 turēt un 0 pārdot. 2026. gadam analītiķi sagaida, ka Repligen gūs 830,23 M USD ieņēmumus un 2,04 USD peļņu uz akciju.
Pēc pašreizējā kursa Repligen akcija maksā 158,55 EUR (176,94 USD).
Repligen akcija (RGEN) tiek kotēta 5 biržās, tostarp: NASDAQ (RGEN), SIX (Zürich) (RGN.SW), Frankfurt (RGN.F), München (RGN.MU), Düsseldorf (RGN.DU).
Repligen Corp is a leading biotech company specializing in the research, development, and manufacturing of products for bioproduction and cell therapy. The company was founded in 1981 and is headquartered in Waltham, Massachusetts. Repligen Corp's business model is based on four different divisions: bioproduction, chromatography, short-term culture media, and cell therapy. These divisions offer a wide range of products for the research and development community as well as the biopharmaceutical industry. The bioproduction division of Repligen Corp offers a variety of products for the production of recombinant proteins, antibodies, and other therapeutics. These include HGGE and Protein-A affinity resins, the TangenX® membrane separation portfolio, and the XCell™ ATF system for perfusion. The chromatography division of Repligen Corp offers a wide range of products for the purification of proteins and other biologics. These include protein-A affinity resins, reversed-phase resins, HIC and ion exchange resins, and more. The short-term culture media division of Repligen Corp specializes in the development of media for cell cultivation. These include the OptiCHO™, OptiPEAK TiterMAX®, and CellBoost™ portfolios. The cell therapy division of Repligen Corp offers strictly regulated products for clinical applications in cell therapy. These include Syntheglas™ peptides and SAVI™ cell therapy products for the treatment of inflammatory diseases in the gastrointestinal tract. Repligen Corp also offers services and support for its products, including technical consulting and support as well as product training. The company works closely with its customers to ensure that its products meet the specific requirements of the research and biopharmaceutical industry. Overall, Repligen Corp has a strong business model based on the development of innovative products for bioproduction and cell therapy. The company is committed to advancing the development of its products and actively participating in the expansion of the bioproduction industry. Answer: Repligen Corp is a biotech company specializing in the research, development, and manufacturing of products for bioproduction and cell therapy. They offer a range of products for protein production, protein purification, cell cultivation, and cell therapy. The company provides services, support, and product training and aims to contribute to the growth of the bioproduction industry.
gaidāmā apgrozījums Repligen ir 830,23 M USD. Šis skaitlis ir balstīts uz pašreizējiem finanšu datiem un atspoguļo uzņēmuma biznesa sniegumu.
gaidāmā peļņa Repligen ir 115,22 M USD. Neto peļņa atspoguļo uzņēmuma rentabilitāti pēc visu izdevumu atskaitīšanas.
Repligen cenas un peļņas rādītājs (P/E) pašlaik ir 86,80. P/E rādītājs salīdzina pašreizējo akcijas cenu ar peļņu uz akciju un palīdz ieguldītājiem novērtēt Repligen akcijas vērtību.
Repligen cenas un apgrozījuma rādītājs (P/S) pašlaik ir 12,05. P/S rādītājs salīdzina tirgus kapitalizāciju ar gada apgrozījumu un kalpo kā Repligen akcijas vērtības mērs.
Repligen Eulerpool kvalitātes rādītājs ir 4/10.
Repligen ISIN ir US7599161095. ISIN (International Securities Identification Number) ir pasaulē unikāls vērtspapīru identifikators.
Repligen WKN ir 870980. WKN (Wertpapierkennnummer) ir sešciparu vācu vērtspapīru identifikācijas numurs.
Repligen tikeris ir RGEN. Tikeris tiek izmantots Repligen akciju tirdzniecībai biržā.
Repligen akcija
Repligen Salīdzināmo uzņēmumu grupa
Repligen Biržas kods
Repligen FIGI
Visi Repligen fundamentālie rādītāji un padziļinātā analīze
Mūsu akciju analīze par Repligen ietver svarīgus finanšu rādītājus, piemēram, apgrozījumu, peļņu, P/E rādītāju, P/S rādītāju, EBIT, kā arī informāciju par dividendēm. Turklāt mēs aplūkojam aspektus kā akcijas, tirgus kapitalizāciju, parādus, pašu kapitālu un saistības no Repligen. Ja meklējat sīkāku informāciju par šīm tēmām, piedāvājam detalizētas analīzes mūsu apakšlapās: